THE US Food and Drug
Administration has approved
the cobas EGFR Mutation Test,
a companion diagnostic for the
cancer drug Tarceva (erlotinib).
It’s the first FDA-approved
companion diagnostic which
detects epidermal growth factor
receptor (EGFR) gene mutations,
which are present in about 10% of
non-small-cell lung cancers.
The test is being approved with an
expanded use for Tarceva as a firstline
treatment for patients with
these cancers who have certain
mutations in the EGFR gene.
The FDA has also granted approval
for Numalize, a new nimodipine
oral solution to treat patients
experiencing symptoms resulting
from subarachnoid haemorrhage.
Nimidopine was previously only
available as a liquid-filled gel cap.The above article was sent to subscribers in Pharmacy Daily's issue from 16 May 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 May 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.